Introduction

The biopharmaceutical industry is shifting toward non-invasive delivery to improve patient compliance. Historically, monoclonal antibodies (mAbs) required intravenous or subcutaneous injection due to their large size and susceptibility to degradation. Recent literature confirms that while standard oral bioavailability for unprotected mAbs is as low as 0.02%, innovative encapsulation and protein engineering can significantly enhance systemic exposure. Creative Biolabs utilizes these insights to develop formulations that protect biologics from the harsh gastrointestinal environment, ensuring therapeutic activity is maintained.

The Market Outlook: The Future is Oral

The custom antibody market is projected to exceed 1.3 billion by 2034, with oral delivery being the primary driver for "biologics-first" discovery. The antibody therapeutics market is shifting from an injection-dominated landscape toward more patient-friendly, "long-acting" delivery methods, with oral antibodies. Oral antibody formulations are expanding from local gastrointestinal treatments to systemic disease management. Currently, research and clinical areas include:

The Challenge: Overcoming the Gastrointestinal Gauntlet

Developing oral antibodies is notoriously difficult due to the harsh physiological environment of the gastrointestinal (GI) tract. To achieve therapeutic efficacy, an oral formulation must survive:

• Acidic Denaturation: The low pH of gastric fluid (pH 1.0-3.5) can rapidly unfold and inactivate complex antibody structures.
• Proteolytic Attack: Enzymes such as pepsin in the stomach and trypsin or chymotrypsin in the small intestine hydrolyze peptide bonds, often leaving less than 20% of the antibody active.
• Epithelial Barrier: The large molecular weight of mAbs (~150 kDa) prevents passive diffusion through the intestinal lining or tight junctions.
• Low Bioavailability: Absolute oral bioavailability in rodents is approximately 0.02%, requiring a thousand-fold increase through technology to reach commercial viability.
• Mucus Penetration: Formulations must navigate the negatively charged mucin layer to reach the absorptive enterocytes.

Fig.1 The oral bioavailability of the humanized mAb in rodents.¹

Our Oral Antibody Formulation Development Service

With over two decades of expertise in antibody engineering and advanced drug delivery, we offer a comprehensive oral antibody formulation development service designed to transform injectable biologics into stable, high-bioavailability oral solid dosage forms. We utilize a multi-disciplinary approach that combines AI-driven in silico screening with proprietary chemical engineering to ensure your lead candidate reaches its destination intact.

Contact Us

Creative Biolabs combines 20 years of protein expertise with 2026-era delivery technologies. We provide a comprehensive oral antibody formulation development service that turns complex proteins into stable, bioavailable oral dosage forms. Contact us for more information about our oral antibody formulation development platform.

Loading case studies...

For research use only. Not intended for any clinical use.